For example, in hormone receptor-positive, HER2neu-positive, and triple-negative forms of breast cancer, FGFR1 amplification is associated with early relapse and poor outcomes [13,14] and also promotes the resistance of luminal B type breast cancer to endocrine therapy [15]. Here, FGFR1 is linked to breast carcinoma.